- Home
- CDXS vs TONX Comparison
CDXS vs TONX Comparison
Compare CDXS & TONX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- TONX
- Stock Information
- Founded
- CDXS 2002
- TONX N/A
- Country
- CDXS United States
- TONX United States
- Employees
- CDXS N/A
- TONX N/A
- Industry
- CDXS Major Chemicals
- TONX Other Consumer Services
- Sector
- CDXS Industrials
- TONX Consumer Discretionary
- Exchange
- CDXS Nasdaq
- TONX Nasdaq
- Market Cap
- CDXS 216.6M
- TONX 248.4M
- IPO Year
- CDXS 2010
- TONX N/A
- Fundamental
- Price
- CDXS $2.65
- TONX $3.69
- Analyst Decision
- CDXS Buy
- TONX
- Analyst Count
- CDXS 2
- TONX 0
- Target Price
- CDXS $11.00
- TONX N/A
- AVG Volume (30 Days)
- CDXS 542.5K
- TONX 868.8K
- Earning Date
- CDXS 10-30-2025
- TONX 11-04-2025
- Dividend Yield
- CDXS N/A
- TONX N/A
- EPS Growth
- CDXS N/A
- TONX N/A
- EPS
- CDXS N/A
- TONX N/A
- Revenue
- CDXS $57,164,000.00
- TONX $4,279,000.00
- Revenue This Year
- CDXS $12.88
- TONX $526.82
- Revenue Next Year
- CDXS $21.64
- TONX $45.45
- P/E Ratio
- CDXS N/A
- TONX N/A
- Revenue Growth
- CDXS N/A
- TONX 4095.10
- 52 Week Low
- CDXS $1.90
- TONX $3.69
- 52 Week High
- CDXS $6.08
- TONX $13.90
- Technical
- Relative Strength Index (RSI)
- CDXS 55.26
- TONX N/A
- Support Level
- CDXS $2.46
- TONX N/A
- Resistance Level
- CDXS $2.76
- TONX N/A
- Average True Range (ATR)
- CDXS 0.16
- TONX 0.00
- MACD
- CDXS 0.02
- TONX 0.00
- Stochastic Oscillator
- CDXS 50.97
- TONX 0.00
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About TONX TON Strategy Company Common Stock
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.